Literature DB >> 1430194

Cancer risks from germline p53 mutations.

T Frebourg1, S H Friend.   

Abstract

Entities:  

Mesh：

Year:  1992        PMID： 1430194      PMCID： PMC443218          DOI： 10.1172/JCI116034

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  44 in total

1.  p53 functions as a cell cycle control protein in osteosarcomas.

Authors:  L Diller; J Kassel; C E Nelson; M A Gryka; G Litwak; M Gebhardt; B Bressac; M Ozturk; S J Baker; B Vogelstein
Journal:  Mol Cell Biol       Date:  1990-11       Impact factor: 4.272

2.  Genetic mechanisms of tumor suppression by the human p53 gene.

Authors:  P L Chen; Y M Chen; R Bookstein; W H Lee
Journal:  Science       Date:  1990-12-14       Impact factor: 47.728

3.  Inherited p53 gene mutations in breast cancer.

Authors:  D Sidransky; T Tokino; K Helzlsouer; B Zehnbauer; G Rausch; B Shelton; L Prestigiacomo; B Vogelstein; N Davidson
Journal:  Cancer Res       Date:  1992-05-15       Impact factor: 12.701

4.  Suppression of malignancy by cell fusion.

Authors:  H Harris; O J Miller; G Klein; P Worst; T Tachibana
Journal:  Nature       Date:  1969-07-26       Impact factor: 49.962

5.  Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life.

Authors:  C A Finlay; P W Hinds; T H Tan; D Eliyahu; M Oren; A J Levine
Journal:  Mol Cell Biol       Date:  1988-02       Impact factor: 4.272

6.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours.

Authors:  L A Donehower; M Harvey; B L Slagle; M J McArthur; C A Montgomery; J S Butel; A Bradley
Journal:  Nature       Date:  1992-03-19       Impact factor: 49.962

7.  Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma.

Authors:  J Toguchida; T Yamaguchi; S H Dayton; R L Beauchamp; G E Herrera; K Ishizaki; T Yamamuro; P A Meyers; J B Little; M S Sasaki
Journal:  N Engl J Med       Date:  1992-05-14       Impact factor: 91.245

8.  Abnormal expression of wild type p53 protein in normal cells of a cancer family patient.

Authors:  D M Barnes; A M Hanby; C E Gillett; S Mohammed; S Hodgson; L G Bobrow; I M Leigh; T Purkis; C MacGeoch; N K Spurr
Journal:  Lancet       Date:  1992-08-01       Impact factor: 79.321

Review 9.  TP53 tumor suppressor gene: a model for investigating human mutagenesis.

Authors:  C Caron de Fromentel; T Soussi
Journal:  Genes Chromosomes Cancer       Date:  1992-01       Impact factor: 5.006

10.  Germ-line and somatic p53 gene mutations in multifocal osteogenic sarcoma.

Authors:  A Iavarone; K K Matthay; T M Steinkirchner; M A Israel
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205
View more
  8 in total

1.  Dominant-negative p53 mutations selected in yeast hit cancer hot spots.

Authors:  R K Brachmann; M Vidal; J D Boeke
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-30       Impact factor: 11.205

2.  Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma.

Authors:  L Diller; E Sexsmith; A Gottlieb; F P Li; D Malkin
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

Review 3.  Exploiting synthetic lethal interactions for targeted cancer therapy.

Authors:  H Christian Reinhardt; Hai Jiang; Michael T Hemann; Michael B Yaffe
Journal:  Cell Cycle       Date:  2009-10-01       Impact factor: 4.534

4.  Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome.

Authors:  T Frebourg; N Barbier; Y X Yan; J E Garber; M Dreyfus; J Fraumeni; F P Li; S H Friend
Journal:  Am J Hum Genet       Date:  1995-03       Impact factor: 11.025

Review 5.  Targeting ATM-deficient CLL through interference with DNA repair pathways.

Authors:  Gero Knittel; Paul Liedgens; Hans C Reinhardt
Journal:  Front Genet       Date:  2015-06-10       Impact factor: 4.599

6.  Association between TP53 gene Arg72Pro polymorphism and Wilms' tumor risk in a Chinese population.

Authors:  Wen Fu; Zhen-Jian Zhuo; Wei Jia; Jinhong Zhu; Shi-Bo Zhu; Ze-Feng Lin; Feng-Hua Wang; Huimin Xia; Jing He; Guo-Chang Liu
Journal:  Onco Targets Ther       Date:  2017-02-23       Impact factor: 4.147

7.  Tumourigenesis associated with the p53 tumour suppressor gene.

Authors:  F Chang; S Syrjänen; A Tervahauta; K Syrjänen
Journal:  Br J Cancer       Date:  1993-10       Impact factor: 7.640

8.  Frequent mutations of p53 gene in oesophageal squamous cell carcinomas with and without human papillomavirus (HPV) involvement suggest the dominant role of environmental carcinogens in oesophageal carcinogenesis.

Authors:  F Chang; S Syrjänen; A Tervahauta; K Kurvinen; L Wang; K Syrjänen
Journal:  Br J Cancer       Date:  1994-08       Impact factor: 7.640
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.